3 New Strong Buy Ratings from Top-Rated Analysts: 01/23/2026

All of these stocks have exceptional Zen Ratings AND excellent forecasts from top-rated analysts:

• InfuSystem Holdings (INFU) gets a boost from the NOPAIN act
• OptimizeRx Corp (OPRX) enjoys expansion 
• Lands' End (LE) is back in fashion 

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

1. InfuSystem Holdings Inc (NYSEMKT: INFU)

InfuSystem Holdings provides health care services specializing in ambulatory infusion pumps for oncology and pain management applications. The company recently received a boost from the NOPAIN Act, which provides separate payment for ambulatory infusion pumps in pain management starting this year. 

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $8.46 — get current quote

Max 1-year forecast: $15.00

Why we're watching:

• Analyst support: The stock only has 2 ratings from analysts we track, but they’re both Strong Buy ratings, with a max 1-year forecast that suggests over 70% upside potential. See them here. 
• Roth Capital analyst Kyle Bauser (top 21%) recently reiterated his Strong Buy rating with a price target that suggests nearly 60% upside, following Q3 2025 earnings, noting that the company's core Oncology business continues to perform well while management focused on opportunities that improved profitability.
• Bauser highlighted that while they reduced revenue estimates, they increased adjusted EBITDA and EPS estimates slightly, with higher estimates and lower share count from buybacks contributing to their adjusted price target.
• Industry ranking context: INFU is currently the #2 highest-rated stock out of 45 in the Medical industry, which carries a solid B Industry Rating.
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — a lot higher than the S&P. 
• Component Grades: The stock demonstrates exceptional Momentum (A grade) and Safety (A grade) component ratings, suggesting the price is right and smart money sees strong potential. See all 7 Zen Component Grades here

2. OptimizeRx Corp (NASDAQ: OPRX)

This digital health technology company recently expanded its point-of-care network and announced a collaboration with Experian to improve healthcare marketing capabilities.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $12.08 — get current quote

Max 1-year forecast: $24.00

Why we're watching:

• Analyst support: The stock has coverage from 3 Wall Street analysts, with 1 Strong Buy rating, 1 Buy rating, and 1 Hold rating, resulting in a Buy consensus. See the ratings
• Stifel Nicolaus analyst David Grossman maintains a Strong Buy rating with an $18 price target — which, if achieved, would represent nearly 50% upside — citing the company's impressive market adaptability and strong positioning for future growth.
• Grossman emphasized OPRX's ability to adapt to market changes and highlighted strategic partnerships expected to enhance market presence, noting strong market position and positive outlook on industry growth.
• Other analysts are bullish, too — the max price forecast for OPRX suggests nearly 100% upside potential. 
• Industry ranking context: OPRX is currently the #2 highest-rated stock out of 45 in the Health Information Service industry, which carries a B Industry Rating.
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — maybe not early-stage NVDA types of gains, but impressive nonetheless. 
• Component Grades: The stock shows impressive Growth and Sentiment scores at A grades, supported by solid Financials (B), though Value, Momentum, Safety, and AI all carry C grades. See all 7 Zen Component Grades here

3. Lands' End (NASDAQ: LE)

The outdoorsy catalog retailer is making big moves. The company is positioned as the top-rated stock in the Apparel industry, with strong earnings growth forecasts driving optimism about its turnaround potential.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $15.25 — get current quote

Max 1-year forecast: $20.00

Why we're watching:

• Analyst support: LE has a mere 1 rating from the analysts we track, but it is resoundingly bullish — a Strong Buy with a price target that suggests over 25% upside potential in the coming year. See the rating
• SMALL CAP CONSUMER RESEARCH analyst Eric M Beder recently reiterated a Strong Buy rating with a $20 price target following the company's Q3 2025 earnings report.
• Analysts are particularly optimistic about the company's earnings trajectory, with forecasted earnings growth of 125.49% annually significantly outpacing the broader Apparel industry's 3.13% growth rate.
• Industry ranking context: LE is currently the #1 highest-rated stock in the Apparel industry, which has an Industry Rating of A.
• Zen Rating highlights: LE ranks in the top 5% of stocks we track based on a 115-factor review, earning an overall A (Strong Buy) rating. It shows strength in Growth and Sentiment, where it earns Component Grades of B, indicating it’s on a positive uptrend and analysts are taking notice. See all 7 Zen Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.